Clinical trial
CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer
NCT00270907 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00270907 |
|---|---|
| Title | CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer |
| Official title | A Phase I Study of CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | CTI BioPharma Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer, Breast Cancer |
| Intervention type | Drug |
| Interventions | CT-2103, Gemcitabine |
| Enrollment | 13 |
| Start date | Dec 1, 2005 |
| Primary completion | Oct 1, 2012 |
| Completion | Oct 1, 2012 |
| First posted | Dec 29, 2005 |
| Last update posted | Feb 13, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: